LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Yusuf, Amman"
  2. AU="Shastri, Jayanthi S."
  3. AU=McMaster Mary L
  4. AU="Ren, Xiaojie"
  5. AU="Grubbs, Griffin L"
  6. AU="Shen, Jianping"
  7. AU="Thuss-Patience, Peter"
  8. AU="Feng, Qingguo"
  9. AU="Mikayla Schowalter"
  10. AU=Milman Evgenia

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Text analysis framework for identifying mutations among non-small cell lung cancer patients from laboratory data.

    Yusuf, Amman / Boyne, Devon J / O'Sullivan, Dylan E / Brenner, Darren R / Cheung, Winson Y / Mirza, Imran / Jarada, Tamer N

    BMC medical research methodology

    2024  Volume 24, Issue 1, Page(s) 63

    Abstract: Background: Laboratory data can provide great value to support research aimed at reducing the incidence, prolonging survival and enhancing outcomes of cancer. Data is characterized by the information it carries and the format it holds. Data captured in ... ...

    Abstract Background: Laboratory data can provide great value to support research aimed at reducing the incidence, prolonging survival and enhancing outcomes of cancer. Data is characterized by the information it carries and the format it holds. Data captured in Alberta's biomarker laboratory repository is free text, cluttered and rouge. Such data format limits its utility and prohibits broader adoption and research development. Text analysis for information extraction of unstructured data can change this and lead to more complete analyses. Previous work on extracting relevant information from free text, unstructured data employed Natural Language Processing (NLP), Machine Learning (ML), rule-based Information Extraction (IE) methods, or a hybrid combination between them.
    Methods: In our study, text analysis was performed on Alberta Precision Laboratories data which consisted of 95,854 entries from the Southern Alberta Dataset (SAD) and 6944 entries from the Northern Alberta Dataset (NAD). The data covers all of Alberta and is completely population-based. Our proposed framework is built around rule-based IE methods. It incorporates topics such as Syntax and Lexical analyses to achieve deterministic extraction of data from biomarker laboratory data (i.e., Epidermal Growth Factor Receptor (EGFR) test results). Lexical analysis compromises of data cleaning and pre-processing, Rich Text Format text conversion into readable plain text format, and normalization and tokenization of text. The framework then passes the text into the Syntax analysis stage which includes the rule-based method of extracting relevant data. Rule-based patterns of the test result are identified, and a Context Free Grammar then generates the rules of information extraction. Finally, the results are linked with the Alberta Cancer Registry to support real-world cancer research studies.
    Results: Of the original 5512 entries in the SAD dataset and 5017 entries in the NAD dataset which were filtered for EGFR, the framework yielded 5129 and 3388 extracted EGFR test results from the SAD and NAD datasets, respectively. An accuracy of 97.5% was achieved on a random sample of 362 tests.
    Conclusions: We presented a text analysis framework to extract specific information from unstructured clinical data. Our proposed framework has shown that it can successfully extract relevant information from EGFR test results.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/genetics ; Laboratories ; NAD ; Lung Neoplasms/diagnosis ; Lung Neoplasms/genetics ; Mutation ; Natural Language Processing ; ErbB Receptors ; Biomarkers ; Electronic Health Records
    Chemical Substances NAD (0U46U6E8UK) ; ErbB Receptors (EC 2.7.10.1) ; Biomarkers
    Language English
    Publishing date 2024-03-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041362-2
    ISSN 1471-2288 ; 1471-2288
    ISSN (online) 1471-2288
    ISSN 1471-2288
    DOI 10.1186/s12874-024-02192-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada.

    Brenner, Darren R / O'Sullivan, Dylan E / Jarada, Tamer N / Yusuf, Amman / Boyne, Devon J / Mather, Cheryl A / Box, Adrian / Morris, Donald G / Cheung, Winson Y / Mirza, Imran

    Lung cancer (Amsterdam, Netherlands)

    2022  Volume 175, Page(s) 60–67

    Abstract: Objectives: While Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors have been shown to be effective in phase III randomized trials, the value of targeted therapies has been challenging to evaluate at the population-level. We examined ... ...

    Abstract Objectives: While Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors have been shown to be effective in phase III randomized trials, the value of targeted therapies has been challenging to evaluate at the population-level. We examined the impact of population-level EGFR testing and treatment on survival outcomes among non-squamous metastatic Non-Small Cell Lung Cancer (NSCLC) patients.
    Materials and methods: Real-world, population-level data were collected from all de novo non-squamous metastatic NSCLC patients in Alberta, Canada from 2004 to 2020. EGFR testing data were collected through Alberta Precision Laboratories. Differences in survival rates and overall survival (OS) pre (2004-2012) and post initiation (post) (2013-2019) testing periods were evaluated using interrupted time series analyses. The impact of testing and subsequent treatment was evaluated using multivariable Cox Proportional Hazards models.
    Results: In total, 4,578 non-squamous metastatic NSCLC patients were diagnosed pre-EGFR testing and 4,457 patients were diagnosed post-EGFR testing (2013-2019). Among patients diagnosed in the pre-EGFR testing period, the 6-month, 1-year, and 2-year survival probabilities were 0.39 (95 % CI: 0.38-0.41), 0.22 (95 % CI: 0.21-0.23), and 0.09 (95 % CI: 0.08-0.10), while the survival probabilities for patients diagnosed in the post-EGFR testing period were 0.45 (95 % CI: 0.43-0.46), 0.29 (95 % CI: 0.27-0.30), and 0.16 (95 % CI: 0.15-0.17), respectively. After adjusting for baseline patient and clinical characteristics, OS in the post-EGFR period was significantly improved compared to the pre-EGFR period (HR: 0.81; 95 % CI: 0.78-0.85). Among patients who were treated with systemic therapy, those tested for an EGFR mutation had significantly greater survival than patients who were not tested HR of 0.81 (95 % CI: 0.70-0.95).
    Conclusion: These results show the considerable impact of population-based molecular testing and subsequent targeted therapies on survival among metastatic NSCLC patients. The estimates here can be used in future studies to evaluate the population-level cost-effectiveness of testing and treatment.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Lung Neoplasms/drug therapy ; Alberta/epidemiology ; ErbB Receptors/genetics ; Mutation ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2022-11-25
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2022.11.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Prevalence, Treatment Patterns, and Outcomes of Individuals with

    O'Sullivan, Dylan E / Jarada, Tamer N / Yusuf, Amman / Hu, Leo Xun Yang / Gogna, Priyanka / Brenner, Darren R / Abbie, Erica / Rose, Jennifer B / Eaton, Kiefer / Elia-Pacitti, Julia / Ewara, Emmanuel M / Pabani, Aliyah / Cheung, Winson Y / Boyne, Devon J

    Current oncology (Toronto, Ont.)

    2022  Volume 29, Issue 10, Page(s) 7198–7208

    Abstract: Real-world evidence ... ...

    Abstract Real-world evidence surrounding
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Gefitinib/therapeutic use ; Afatinib/therapeutic use ; Erlotinib Hydrochloride/therapeutic use ; ErbB Receptors/genetics ; Prevalence ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Platinum/therapeutic use ; Antineoplastic Agents/therapeutic use ; Exons ; Mutation ; Alberta
    Chemical Substances Gefitinib (S65743JHBS) ; Afatinib (41UD74L59M) ; Erlotinib Hydrochloride (DA87705X9K) ; ErbB Receptors (EC 2.7.10.1) ; Platinum (49DFR088MY) ; Antineoplastic Agents
    Language English
    Publishing date 2022-09-30
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1236972-x
    ISSN 1718-7729 ; 1198-0052
    ISSN (online) 1718-7729
    ISSN 1198-0052
    DOI 10.3390/curroncol29100567
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top